<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List href="./Page3_files/filelist.xml">
<link rel=Edit-Time-Data href="./Page3_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title> </title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>jennifer</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>McDowall</o:LastAuthor>
  <o:Revision>18</o:Revision>
  <o:TotalTime>791</o:TotalTime>
  <o:Created>2004-11-17T15:22:00Z</o:Created>
  <o:LastSaved>2004-12-06T17:37:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>888</o:Words>
  <o:Characters>5067</o:Characters>
  <o:Company>EMBL-EBI</o:Company>
  <o:Lines>42</o:Lines>
  <o:Paragraphs>10</o:Paragraphs>
  <o:CharactersWithSpaces>6222</o:CharactersWithSpaces>
  <o:Version>9.6926</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>75</w:Zoom>
  <w:ActiveWritingStyle Lang="EN-GB" VendorID="64" DLLVersion="131077"
   NLCheck="1">3</w:ActiveWritingStyle>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:16.0pt;
	font-family:Arial;
	mso-font-kerning:16.0pt;}
h3
	{mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:13.0pt;
	font-family:Arial;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:72.0pt 89.85pt 72.0pt 89.85pt;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1029"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB link=blue vlink=blue style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoNormal><a href="http://www.ebi.ac.uk/interpro/"
title="To the InterPro database"><span style='text-decoration:none;text-underline:
none'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:113.25pt;
 height:36.75pt'>
 <v:imagedata src="./Page3_files/image001.jpg" o:title="InterPro_logo"/>
</v:shape><![endif]--><![if !vml]><img border=0 width=151 height=49
src="./Page3_files/image001.jpg" v:shapes="_x0000_i1025"><![endif]></span></a></p>

<h1 align=center style='text-align:center'><span style='font-size:28.0pt;
mso-bidi-font-size:16.0pt;color:navy'>Ubiquitin<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1><span style='color:navy'>The Many Roles of Ubiquitin<o:p></o:p></span></h1>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Different
types of UB modifications are capable of transmitting unique signals.<span
style="mso-spacerun: yes">  </span>Ubiquitinylation can be used to modify a
protein’s activity, to change its subcellular location, or to alter
protein-protein interactions.<span style="mso-spacerun: yes">  </span>The addition
of a single UB molecule (mono-ubiquitinylation) is a reversible modification
used to alter the function and localisation of key proteins in several
processes, including transcription, histone function, and membrane trafficking.<span
style="mso-spacerun: yes">  </span>The addition of poly-UB chains linked via
Lys(6) or Lys(63) residues may also modulate a protein’s function or location;
in particular, Lys(63) poly-UB-linked proteins are known to be involved in
processes such as signalling DNA repair and DNA damage tolerance, inflammatory response,
protein trafficking and signal transduction through kinase activation.<span
style="mso-spacerun: yes">  </span>The structural differences achieved by
attaching different types of UB modifications may account for their unique
differences in signalling capabilities.<span style="mso-spacerun: yes"> 
</span>The type of UB modification attached to a target protein is determined
through the E2 and E3 enzymes.<span style="mso-spacerun: yes">  </span>Often
processes are controlled by a combination of UB-associated methods; for instance,
frequent targets of ubiquitinylation are transcription factors, whose function
is modulated both by UB-induced degradation, as well as by UB-controlled
nuclear-cytoplasmic trafficking of transcription factors and modified
substrates.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>A few of the
processes that non-proteolytic ubiquitinylation is involved in are listed
below:</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Protein processing<o:p></o:p></i></h3>

<p class=MsoBodyText><span style='mso-tab-count:1'>            </span>Lys(6) poly-UB
chains can be recognised by the 26S proteasome as processing signals, rather
than degradation signals.<span style="mso-spacerun: yes">  </span>For example,
Lys(6) poly-ubiquitinylation of the breast and ovarian cancer tumour suppressor
BRCA1 will be edited and de-ubiquitinylated by the 26S proteasome (stabilised)
rather than degraded.<span style="mso-spacerun: yes">   </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Cell signalling<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'>Ubiquitinylation
can reversibly alter the way a protein is recognised by a cell, much in the
same way as occurs with modifications by phosphorylation.<span
style="mso-spacerun: yes">  </span>These modifications can affect a variety of
different signalling systems.<span style="mso-spacerun: yes">  </span>For
example, Lys(63) poly-UB-linked chains can signal activation of the I<span
style='font-family:Symbol'>k</span>B<span style='font-family:Symbol'>a</span>
kinase (IKK) in the inflammatory signalling pathway.<span style="mso-spacerun:
yes">  </span>IKK activation causes the degradation of I<span style='font-family:
Symbol'>k</span>B<span style='font-family:Symbol'>a</span>, which leads to the
activation and translocation of the transcription factor NF<span
style='font-family:Symbol'>k</span>B to the nucleus, where it activates the
genes required to mount an inflammatory response.</p>

<p class=MsoNormal style='text-align:justify;text-indent:36.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Transcription regulation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Histone
modifications are key determinants in gene expression, in part through
providing interaction surfaces for proteins that impact on chromatin
accessibility.<span style="mso-spacerun: yes">  </span>These modifications
include acetylation, methylation, phosphorylation and ubiquitinylation, and
they often work synergistically.<span style="mso-spacerun: yes"> 
</span>Modifications on different histones, or at different positions within a
histone, can have opposite effects.<span style="mso-spacerun: yes">  </span>The
mono-ubiquitinylation of histone H2B is required for gene activation, possibly
by the recruitment of an acetyltransferase complex.<span style="mso-spacerun:
yes">  </span>Ubiquitinylated H2B is also required for histone H3 methylation
at positions Lys(4) and Lys(79), which in turn is necessary for histone
activation and subsequent gene expression.<span style="mso-spacerun: yes"> 
</span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>X inactivation<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>The
ubiquitinylation of histone H2A has an opposite effect to that of H2B, namely
gene silencing.<span style="mso-spacerun: yes">  </span>Histone H2A
ubiquitinylation is an abundant modification (5-15% of total H2A) in higher
eukaryotes, and occurs on the inactive X chromosome in female mammals.<span
style="mso-spacerun: yes">  </span>H2A ubiquitinylation is associated with the
recruitment of Polycomb repressor complex 1 (PRC1) of the Polycomb group (PcG)
proteins, which are memory factors involved in chromatin-related heritable gene
silencing.<span style="mso-spacerun: yes">  </span>Two of the core PRC1
proteins, PSC and dRING, have a RING finger domain that is characteristic of UB
and of certain E3 ligases.<span style="mso-spacerun: yes">  </span>It is
unclear whether H2A ubiquitinylation also plays a part in the methylation of
histone H3 at position Lys(27), which is central to PcG-dependent
silencing.<span style="mso-spacerun: yes">  </span></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>DNA damage tolerance<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Lys(63)
poly-UB-modifications are known to be involved in the tolerance of DNA
damage.<span style="mso-spacerun: yes">  </span>These modifications occur on
the DNA polymerase processing factor PCNA (proliferating cell nuclear antigen),
which trimerises to encircle the template DNA strand during replication to
serve as a scaffold for accessory factors.<span style="mso-spacerun: yes"> 
</span>The access of accessory proteins to PCNA is partly determined by the
type of PCNA UB-modification, which in turn determines the fate of the DNA
lesion.<span style="mso-spacerun: yes">  </span>Mono-ubiquitinylation of PCNA
can lead to the recruitment of a trans-lesion polymerise that instigates an error-prone
method of DNA lesion bypass, whereas poly-Lys(63) ubiquitinylation of PCNA
leads to an error-free process that may involve a poly-UB-dependent switch of
the DNA template strand.</p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h3><i>Membrane trafficking<o:p></o:p></i></h3>

<p class=MsoNormal style='text-align:justify'><span style='mso-tab-count:1'>            </span>Many
signalling receptors and adaptor proteins require mono-ubiquitinylation to recruit
proteins of the endocytic and exocytic pathways, and for sorting cargo for
vesicular trafficking.<span style="mso-spacerun: yes">  </span>For instance,
mono-ubiquitinylation acts as a signal for receptor endocytosis and for targeting
to the lysosomes, where non-UB-mediated proteolysis occurs.<span
style="mso-spacerun: yes">  </span>Genetic defects that act to disrupt
UB-controlled sorting of cargo for trafficking are often linked to aberrations
in cell growth, and may result in oncogenic transformation.<span
style="mso-spacerun: yes">  </span>For example, c-Cbl is an E3 ligase that
attaches UB to tyrosine-phosphorylated receptors for the epidermal growth
factor (EGF), thereby accelerating their internalisation in tiny membranous
sacs called endosomes - these endosomes are either delivered to the lysosome
for degradation, or recycled back to the cell membrane.<span
style="mso-spacerun: yes">  </span>Cancer-causing c-Cbl mutants have been found
to either block receptor internalisation or enhance recycling of active receptors.<span
style="mso-spacerun: yes">  </span>On the negative side, UB is involved in
enabling viruses such as HIV and Ebola to make their way to the cell surface
after replicating inside the cell.</p>

<p class=MsoBodyText><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></p>

<h1 align=center style='text-align:center'>Next:<span style="mso-spacerun:
yes">  </span><a href="Page4.htm">What InterPro Tells Us</a></h1>

<h1 align=center style='text-align:center'>Previous:<span style="mso-spacerun:
yes">  </span><a href="Page2.htm">Ubiquitin-mediated Protein Degradation</a></h1>

</div>

</body>

</html>
